Baseline characteristics of the study volunteers
| n | Age (range) | Males | ICS (%) | ICS dose (range) | FEV1/FVC (95% CI) | PC20 (95% CI) | |
|---|---|---|---|---|---|---|---|
| Recruited | 104 | 26.7 (9–59) | 38 | 65 (63) | 336 (0–1500) | 77.5% (75.3 to 79.6) | 1.42 (1.15 to 1.75) |
| Withdrew before randomisation | 43 | 26.6 (10–59) | 19 | 31 (72) | 488 (0–1500) | 74.5% (71.4 to 77.6)1-150 | 1.08 (0.76 to 1.20)1-150 |
| Randomised | 61 | 27.0 (9–59) | 19 | 34 (56) | 228 (0–1500) | 79.6% (76.7 to 82.4)1-150 | 1.72 (1.33 to 2.23)1-150 |
| Withdrew after randomisation | 12 | 25 (9–54) | 4 | 6 (50) | 163 (0–750) | 80.2% (75.9 to 84.5) | 1.29 (0.57 to 2.88) |
| Completed study | 49 | 27.4 (10–59) | 15 | 28 (57) | 244 (0–1500) | 79.4% (76.0 to 82.8) | 1.85 (1.41 to 2.42) |
ICS = number taking inhaled corticosteroids before joining the study; ICS dose = mean daily dose of inhaled corticosteroids in μg/day. PC20 = geometric mean PC20methacholine before joining the study in mg/ml.
↵1-150 p<0.05 between withdrew before randomisation and randomised groups.